Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 15/20 | 0.63 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685226 | 1.00 | GPR142 (0.63) | GPR142WNT3ATP53CYP3A4KLKB1 | |
| SCHEMBL2684856 | 0.91 | GPR142 (0.75) | GPR142WNT3ATP53 | |
| SCHEMBL2684875 | 0.91 | GPR142 (0.75) | GPR142WNT3ATP53 | |
| SCHEMBL2684414 | 0.90 | GPR142 (0.65) | GPR142WNT3A | |
| SCHEMBL2684412 | 0.90 | GPR142 (0.65) | GPR142WNT3A | |
| SCHEMBL2685290 | 0.89 | GPR142 (0.79) | GPR142WNT3ATP53KLKB1 | |
| SCHEMBL2685305 | 0.89 | GPR142 (0.79) | GPR142WNT3ATP53KLKB1 | |
| SCHEMBL2685322 | 0.89 | GPR142 (0.62) | GPR142WNT3ATP53CYP3A4KLKB1 | |
| Hydrochloric Acid SCHEMBL2683769 | 0.89 | GPR142 (0.77) | GPR142WNT3ATP53KLKB1 | |
| SCHEMBL2685324 | 0.89 | GPR142 (0.62) | GPR142WNT3ATP53CYP3A4KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2010093849-A2 | PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | GPR142 2779/4885WNT3A 4600/4885TP53 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.